A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer
James JR, Oliveira MI, Carmo AM, Iaboni A, Davis SJ. (2006), Nat Methods. 3, 1001-6
The Davis Lab takes a structural approach to immunity-related questions – when it can be applied – because we think it offers the best types of answers.
Situated within the Weatherall Institute of Molecular Medicine (WIMM) and MRC Translational Immune Discovery Unit, the Davis Lab is home to varying numbers of post-doctoral researchers, PhD students and interns, but a great deal of our success has also depended on the work of four outstanding research assistants, Jan Fennelly, Mai Vuong, Heather Brouwer and Jemma McBride. Encouraged by its position within the WIMM, which is itself a very special place to work, the Davis Lab has a strong social side, which helps new students ‘find their feet’ and fosters collaborative interactions.
Top Ten Papers
-
-
Crystal structure of a soluble CD28-Fab complex
Evans EJ, Esnouf RM, Manso-Sancho R, Gilbert RJ, James JR, Yu C, Fennelly JA, Vowles C, Hanke T, Walse B, Hünig T, Sørensen P, Stuart DI, Davis SJ. (2005), Nat Immunol. 6, 271-9
-
The T cell surface – how well do we know it?
Evans EJ, Hene L, Sparks LM, Dong T, Retiere C, Fennelly JA, Manso-Sancho R, Powell J, Braud VM, Rowland-Jones SL, McMichael AJ, Davis SJ. (2003), Immunity. 19, 213-23
-
The interaction properties of costimulatory molecules revisited
Collins AV, Brodie DW, Gilbert RJ, Iaboni A, Manso-Sancho R, Walse B, Stuart DI, van der Merwe PA, Davis SJ. (2002), Immunity. 17, 201-10
-
LICOS, a primordial costimulatory ligand?
Brodie D, Collins AV, Iaboni A, Fennelly JA, Sparks LM, Xu XN, van der Merwe PA, Davis SJ. (2000), Curr Biol. 10, 333-6
-
Structure and dimerization of a soluble form of B7-1
Ikemizu S, Gilbert RJ, Fennelly JA, Collins AV, Harlos K, Jones EY, Stuart DI, Davis SJ. (2000), Immunity. 12, 51-60
-
The role of charged residues mediating low affinity protein-protein recognition at the cell surface by CD2
Davis SJ, Davies EA, Tucknott MG, Jones EY, van der Merwe PA. (1998), Proc Natl Acad Sci U S A. 95, 5490-4
-
The structure and ligand interactions of CD2: implications for T-cell function
Davis SJ, van der Merwe PA. (1996), Immunol Today. 17, 177-87
-
Expression of soluble recombinant glycoproteins with predefined glycosylation: application to the crystallization of the T-cell glycoprotein CD2
Davis SJ, Puklavec MJ, Ashford DA, Harlos K, Jones EY, Stuart DI, Williams AF. (1993), Protein Eng. 6, 229-32
-
Crystal structure at 2.8 Å resolution of a soluble form of the cell adhesion molecule CD2
Jones EY, Davis SJ, Williams AF, Harlos K, Stuart DI. (1992), Nature. 360, 232-9
Ex-students share their experience of studying at the Davis Lab
-
Hussain Abidi
Originally from Pakistan, Hussain was keen to study for his PhD at a top UK university. He applied to several labs in Oxford and Cambridge, and visited the UK to visit the labs and their professors.
-
James Felce
James is currently a post-doc, working with Simon at the Davis lab in Oxford. He studied for his PhD under Simon’s direction and prior to that he studied Biochemistry for his undergraduate degree here in Oxford too.
-
Ricardo Fernandes
Ricardo studied for his PhD under Simon’s supervision and found the lab – and the wider environment of the WIMM – an inspiring place to study.
-
Xiaoxiao Cheng
Xiaoxiao applied to study at the Davis Lab due to its reputation in immunology research, which reflected her own interests in the field.
Weatherall Institute of Molecular Medicine (WIMM)
The WIMM faculty brings together scientists and clinicians working in collaboration with the National Institute of Health Research, the NHS and commercial companies to improve the diagnosis and treatment of human diseases.
There are currently approximately 450 research and support staff in the WIMM. This includes about 50 group leaders, 130 post-docs, and 140 graduate students within 4400 sq. m of research space.
The major sources of funding are the Medical Research Council (UK), the National Institute of Health Research (via the Oxford Biomedical Research Centre, BRC) and Medical Charities (e.g. Cancer Research UK, the Wellcome Trust and Leukaemia & Lymphoma Research).
